OncoMatch/Clinical Trials/NCT06766916
Crisugabalin for Radiotherapy-Related Neuropathic Pain
Is NCT06766916 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Crisugabalin and Pregabalin for neuropathic pain.
Treatment: Crisugabalin · Pregabalin — The purpose of this study is to evaluate whether Crisugabalin has similar efficacy compared to Pregabalin in reducing radiotherapy-related neuropathic pain (RRNP) in patients with head and neck cancers.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Must have received: radiotherapy
head and neck tumors treated with radiotherapy at least 6 months prior to screening
Cannot have received: pregabalin
Use of pregabalin/crisugabalin within 4 weeks before screening
Cannot have received: crisugabalin
Use of pregabalin/crisugabalin within 4 weeks before screening
Cannot have received: pregabalin
Previous use of pregabalin ≥300 mg/day deemed ineffective
Cannot have received: gabapentin
Previous use of gabapentin ≥1200 mg/day deemed ineffective
Lab requirements
Blood counts
Neutrophil count <1.5×10⁹/L, platelet count <90×10⁹/L, or hemoglobin <100 g/L excluded
Kidney function
eGFR <60 mL/min/1.73 m² or undergoing dialysis excluded
Liver function
ALT or AST >3× ULN, or TBIL >1.5× ULN excluded
Severe abnormalities in hematological, hepatic, or renal function, as evidenced by: Hematology: Neutrophil count <1.5×10⁹/L, platelet count <90×10⁹/L, or hemoglobin <100 g/L. Liver function: ALT or AST >3× ULN, or TBIL >1.5× ULN. Renal function: eGFR <60 mL/min/1.73 m² or undergoing dialysis. Creatine kinase >2× ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify